Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2018 1
2019 1
2020 2
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study.
Lehmann J, de Ligt KM, Tipelius S, Giesinger JM, Sztankay M, Voigt S, van de Poll-Franse LV, Rumpold G, Weger R, Willenbacher E, Willenbacher W, Holzner B. Lehmann J, et al. Among authors: weger r. J Med Internet Res. 2023 Aug 22;25:e46017. doi: 10.2196/46017. J Med Internet Res. 2023. PMID: 37606979 Free PMC article.
The cancer patient's perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic.
Koinig KA, Arnold C, Lehmann J, Giesinger J, Köck S, Willenbacher W, Weger R, Holzner B, Ganswindt U, Wolf D, Stauder R. Koinig KA, et al. Among authors: weger r. Cancer Med. 2021 Jun;10(12):3928-3937. doi: 10.1002/cam4.3950. Epub 2021 May 10. Cancer Med. 2021. PMID: 33973411 Free PMC article.
Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal.
Lehmann J, Buhl P, Giesinger JM, Wintner LM, Sztankay M, Neppl L, Willenbacher W, Weger R, Weyrer W, Rumpold G, Holzner B. Lehmann J, et al. Among authors: weger r. J Med Internet Res. 2021 Jun 8;23(6):e26022. doi: 10.2196/26022. J Med Internet Res. 2021. PMID: 34100765 Free PMC article.
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, Wöll E, Verdorfer I, Gastl G, Willenbacher W, Weger R, Nachbaur D, Wolf D, Gunsilius E, Zschocke J, Steiner N. Locher M, et al. Among authors: weger r. Am J Hematol. 2020 Dec;95(12):1562-1571. doi: 10.1002/ajh.25994. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32936982 Free PMC article. Clinical Trial.
Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.
Sztankay M, Neppl L, Wintner LM, Loth FL, Willenbacher W, Weger R, Weyrer W, Steurer M, Rumpold G, Holzner B. Sztankay M, et al. Among authors: weger r. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13154. doi: 10.1111/ecc.13154. Epub 2019 Aug 29. Eur J Cancer Care (Engl). 2019. PMID: 31465136 Free PMC article.
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E, Willenbacher W, Weger R, Dominik W, Manzl C, Brunner A. Willenbacher E, et al. Among authors: weger r. Ann Hematol. 2020 Sep;99(9):2125-2132. doi: 10.1007/s00277-020-04124-0. Epub 2020 Jul 1. Ann Hematol. 2020. PMID: 32613279 Free PMC article.
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.
Willenbacher W, Willenbacher E, Zelle-Rieser C, Biedermann R, Weger R, Jöhrer K, Brunner A. Willenbacher W, et al. Among authors: weger r. Leuk Lymphoma. 2016;57(6):1478-81. doi: 10.3109/10428194.2015.1099646. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26413883 No abstract available.
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. Antlanger M, et al. Among authors: weger r. BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0. BMC Cancer. 2018. PMID: 30342509 Free PMC article.
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W; Austrian Myeloma Registry (AMR). Willenbacher E, et al. Among authors: weger r. PLoS One. 2016 Mar 3;11(3):e0147381. doi: 10.1371/journal.pone.0147381. eCollection 2016. PLoS One. 2016. PMID: 26937956 Free PMC article.
11 results